- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02355106
Prospective, Multicenter, Investigation of the Adagio Cryoablation System in Subjects With Atrial Flutter
May 21, 2019 updated by: Adagio Medical
A Prospective, Multicenter, Investigation of the Adagio PolarStar System in Subjects With Atrial Flutter
The objective of the study is to demonstrate the safety and feasibility of the Adagio System in subjects with Atrial Flutter.
Study Overview
Study Type
Interventional
Enrollment (Actual)
17
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aalst, Belgium, 9300
- OLV Hospital
-
-
-
-
-
Nieuwegein,, Netherlands
- St. Antonius Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Two symptomatic episodes of typical AFl (or chronic atrial flutter) during the one-year period prior to enrollment. This may include typical AFl occurring while receiving anti-arrhythmic drug (AAD) therapy for non-AFl tachyarrhythmia, including atrial fibrillation (AF).
- At least one episode of typical (clockwise or counterclockwise) atrial flutter documented by 12 lead electrocardiogram (ECG) within 6 months prior to enrollment.
- Subject has been diagnosed with symptomatic AFl
- Subject is at least 18 and ≤75 years of age.
- Subject is able and willing to give informed consent
Exclusion Criteria:
- Intra-cardiac thrombus has not been eliminated in subjects exposed to less than 4 weeks of therapeutic anticoagulation and a TEE (trans-esophageal echocardiogram) and/or CT did not conclusively rule out thrombus
- Subject developed persistent AF at least once in history (electrical or pharmacological cardioversion after 48h or episode duration >7 days).
Subject had any previous left atrial ablation.
- Subject had any previous cardiac surgery, e.g. prosthetic valves, except in the case of an isolated coronary bypass surgery performed more than three months prior to the procedure.
- Subject has permanent pacemaker or defibrillator implant.
- Subject has 2° type II, 3° degree atrioventricular (AV) block or left/right bundle branch block pattern
- Subject has unstable angina pectoris.
- Subject has history of previous myocardial infarction (MI) or percutaneous intervention during the last three months or planned in the next 3 months.
Subject has symptomatic carotid stenosis.
- Subject has chronic obstructive pulmonary disease with detected pulmonary hypertension or any other evidence of significant lung disease.
- Subject has any contraindication for oral anticoagulation.
- Subject has any history of previous transient ischemic attack (TIA) or stroke.
- Subject has known intra-cardiac thrombus formation.
- Subject has any significant congenital heart defect corrected or not (except for patent foramen ovale that is allowed).
- Subject has evidence of congestive heart failure (NYHA class II, III or IV) in sinus rhythm.
- Subject has hypertrophic cardiomyopathy.
- Subject has abnormal long or short QT interval, signs of Brugada syndrome, known inheriting ion channel disease on the family, arrhythmogenic right ventricular dysplasia.
- Subject has sarcoidosis.
- Subject has myxoma.
- Subject has thrombocytosis (platelet count > 600,000 / μl) or thrombocytopenia (platelet count <100,000 / μl).
- Subject has any untreated or uncontrolled hyperthyroidism or hypothyroidism.
- Subject has renal dysfunction with glomerular filtration rate < 60 ml/min/1.72m2.
- Subject has a reversible causes for AF like alcoholism.
- Subject is a pregnant woman or woman of childbearing potential not on adequate birth control: only woman with a highly effective method of contraception [oral contraception or intra-uterine device] (who must have a negative pregnancy test within 1 week of randomization) or sterile woman can be enrolled.
- Subject is a breastfeeding woman.
- Subject has an active systemic infection.
- Subject is unwilling or unable to comply fully with study procedures and follow-up due to any disease condition, which can raise doubt about compliance and influencing the study outcome especially any kind of cancer requiring ongoing in-hospital treatment, severe bleeding in history or a suspected pro-coagulant state.
- Legal incapacity or evidence that a subject cannot understand the purpose and risks of the study or inability to comply fully with study procedures and follow up.
- Subject has a life expectancy of ≤ 1 year.
- Subject is participating in any other clinical study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Atrial flutter Ablation
|
Atrial flutter Ablation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety measured by the percentage of subjects experiencing cardiovascular specific adverse events (CSAE) within thirty 30 days of the ablation procedure.
Time Frame: 30 DAYS
|
30 DAYS
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute Success measured by Percentage of subjects with termination of AFl and complete bidirectional conduction block across the subeustachian (cavo-tricuspid) isthmus at the end of the ablation procedure.
Time Frame: 30 minutes
|
30 minutes
|
|
Outcome success
Time Frame: 30 days
|
Percent of subjects with absence of AFl at 30 days (30 day ECG and as reported by subject or holter monitor)
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2015
Primary Completion (Actual)
May 1, 2019
Study Completion (Actual)
May 21, 2019
Study Registration Dates
First Submitted
January 27, 2015
First Submitted That Met QC Criteria
January 30, 2015
First Posted (Estimate)
February 4, 2015
Study Record Updates
Last Update Posted (Actual)
May 22, 2019
Last Update Submitted That Met QC Criteria
May 21, 2019
Last Verified
December 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CS-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Flutter
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
University of PennsylvaniaWithdrawnTypical Atrial Flutter | Risk Factors With Future Development of Atrial FlutterUnited States
-
Angelo BivianoCompleted
-
Kaiser PermanenteActive, not recruitingAtrial Fibrillation and FlutterUnited States
-
Charles University, Czech RepublicCompleted
-
Hospital Universitario Central de AsturiasJohnson & JohnsonUnknown
-
Hangzhou Dinova EP Technology Co., LtdNot yet recruiting
-
University of ManchesterManchester University NHS Foundation TrustWithdrawn
-
Abbott Medical DevicesCompletedTypical Atrial FlutterUnited States, Canada
-
Abbott Medical DevicesCompletedTypical Atrial FlutterUnited States, Canada
Clinical Trials on PolarStart System
-
ResMedCompleted
-
Federal University of São PauloCompletedAdverse Reaction to Systemic AgentsBrazil
-
KineticureCompletedOsteoarthritis | Knee PainUnited States
-
Smith & Nephew, Inc.CompletedDiabetic Foot Ulcers | Venous Leg UlcersUnited States, Canada
-
Molnlycke Health Care ABCompletedEvaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.Diabetes | Foot UlcersUnited Kingdom
-
Zahedan University of Medical SciencesUnknownPain, Postoperative Pain Pathologic Processes Postoperative Complications Signs and Symptoms
-
University of British ColumbiaNot yet recruitingPersistent Developmental Stutter | Childhood-Onset Fluency Disorder (Stuttering)
-
National Institute of Neurological Disorders and...Recruiting
-
Buckinghamshire Healthcare NHS TrustUnknown